Campbell & CO Investment Adviser LLC Buys Shares of 6,210 Repligen Corporation $RGEN

Campbell & CO Investment Adviser LLC bought a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,210 shares of the biotechnology company’s stock, valued at approximately $772,000.

Several other large investors have also modified their holdings of the business. EFG Asset Management North America Corp. raised its position in shares of Repligen by 149.8% during the 2nd quarter. EFG Asset Management North America Corp. now owns 32,286 shares of the biotechnology company’s stock worth $4,015,000 after purchasing an additional 19,363 shares during the last quarter. South Dakota Investment Council purchased a new position in Repligen during the second quarter worth $236,000. State of Michigan Retirement System raised its holdings in shares of Repligen by 0.8% in the second quarter. State of Michigan Retirement System now owns 12,553 shares of the biotechnology company’s stock worth $1,561,000 after acquiring an additional 100 shares during the last quarter. Geneva Capital Management LLC lifted its position in shares of Repligen by 239.6% in the second quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after acquiring an additional 343,991 shares in the last quarter. Finally, Center for Financial Planning Inc. boosted its stake in shares of Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 126 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Stock Performance

NASDAQ:RGEN opened at $150.56 on Friday. The company has a market cap of $8.48 billion, a P/E ratio of 7,531.77, a P/E/G ratio of 3.32 and a beta of 1.14. The firm’s 50 day moving average is $140.48 and its two-hundred day moving average is $129.71. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.04. The company had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Anthony Hunt sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $156.88, for a total value of $3,922,000.00. Following the transaction, the director directly owned 100,743 shares in the company, valued at $15,804,561.84. This trade represents a 19.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RGEN. HSBC initiated coverage on shares of Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 target price for the company. Wells Fargo & Company reduced their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 30th. Canaccord Genuity Group lifted their target price on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price target on Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Finally, Barclays raised their price objective on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.